Navigation Links
Timothy I. Still Appointed CEO at Accumetrics
Date:10/30/2008

SAN DIEGO, Oct. 30 /PRNewswire/ -- Accumetrics, Inc. has appointed Timothy I. Still to the additional position of Chief Executive Officer. Mr. Still has been serving in the capacity of President and Chief Operating Officer for the company since earlier this year.

"Tim has the right combination of industry, management, and startup experience for our Board," says Tony Arnerich, General Partner of Arnerich & Massena and Executive Chairman of the Board at Accumetrics. "His commercialization expertise and diagnostic market experience will be invaluable as we build key partnerships and move forward with the commercialization of our technology."

Mr. Still's background includes over 18 years of sales, marketing and business development experience in healthcare and medical diagnostics. He has extensive experience in designing and implementing highly focused sales and marketing strategies within both large and small companies.

Prior to Accumetrics, Mr. Still was Executive Vice President and Chief Commercial Officer for HemoSense, a medical diagnostic company located in San Jose, California. He was instrumental in building HemoSense into a rapidly growing, publicly traded company which was acquired by Inverness Medical in November 2007.

Before joining HemoSense, Mr. Still served as Vice President of Sales and Marketing for Cholestech Corporation, and served in a variety of sales, marketing and business development roles for Boehringer Mannheim Corporation (now Roche Diagnostics).

Mr. Still received a B.S. degree (with Honors) in Biological Sciences from the University of California at Davis, and an MBA (Deans Scholar) in Marketing and Entrepreneurship from the University of Southern California.

About Accumetrics (http://www.accumetrics.com):

Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

VerifyNow is the first simple and rapid system for measuring the individual response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, Plavix(R), ReoPro(R), and Integrilin(R), the VerifyNow system provides a valuable tool to help physicians make informed treatment decisions.

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc., ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of Sanofi-Aventis.

CONTACT: Jules Abraham

Lippert Heilshorn & Associates

212-838-3777

jabraham@lhai.com


'/>"/>
SOURCE Accumetrics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. HeartWare Appoints Timothy J. Barberich to Board of Directors
2. Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
3. Wyeth Announces Election of Timothy P. Cost as Senior Vice President, Corporate Affairs
4. SRA Names Timothy J. Atkin Senior Vice President of Global Health Business; Appoints Mike Toner Global Health Unit Chief Financial Officer
5. CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer
6. Excalibur - Transforming Biotech Deals can Still be Achieved
7. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
8. Still River Systems Announces Operation of the Worlds Highest Magnetic Field Cyclotron
9. Federal nanotech risk research plan still comes up short
10. Lethal Human H5N1 Influenza Virus Replikin Gene Still Upregulated
11. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... VILLAGE, Calif. , March 24, 2017   ... dermatology and aesthetics company, today announced that Richard ... Officer, effective March 24.   Peterson, who brings ... succeed John Smither , who is retiring at ... Sienna in an advisory capacity. Peterson joins Sienna from ...
(Date:3/23/2017)...  Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a ... solid tumor cancers, today announced that yesterday it ... last Friday, March 17, 2017. ... totaling 28,843,692 shares, comprised of 18,843,692 common shares ... Class C Warrants pre-funded at the closing at ...
(Date:3/23/2017)... , March 23, 2017 Kineta, ... development of novel therapies in immuno-oncology, today announced ... lead" small molecule compounds that activate interferon response ... pathways and demonstrate immune-mediated tumor regression in a ... the study who demonstrated complete tumor regression to ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... today announced the hire of Dr. Sigmund “Sig” Floyd as Vice President ? ... partnerships and joint development activities. , “Dr. Floyd’s career has spanned 30 years ...
Breaking Biology Technology:
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access System ... over the next decade to reach approximately $1,580 million by 2025. ... forecasts for all the given segments on global as well as ...
(Date:3/22/2017)... , March 21, 2017 Vigilant ... company serving law enforcement agencies, announced today the appointment ... as director of public safety business development. ... law enforcement experience, including a focus on the aviation ... his most recent position, Mr. Sheridan served as the ...
(Date:3/9/2017)... , Australia , March 9, ... study data at the prestigious World Lung Imaging Workshop ... Andreas Fouras , was invited to deliver the ... pulmonary medicine. This globally recognised event brings together leaders ... share the latest developments in lung imaging. ...
Breaking Biology News(10 mins):